Debate: Does it matter how you lower blood pressure? by Alderman, Michael H
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Commentary
Debate: Does it matter how you lower blood pressure?
Michael H Alderman
Albert Einstein College of Medicine, Bronx, New York, USA
Abstract
Whether it matters how pressure is lowered has been debated since antihypertensive
drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke
benefit predicted by a given difference in blood pressure was achieved, the results for
myocardial infarction were roughly half that expected. This suggested that adverse drug
effects of diuretics and b-blockers might have detracted from their hypotensive effects.
Trials with newer antihypertensive classes have revealed superior effects on outcomes
associated with converting enzyme inhibitor use, and that a-blockers are less
cardioprotective than diuretics. These studies establish that simple blood pressure
reduction is an inadequate guide to therapy. The challenge now will be to determine the
optimal therapy for each hypertensive patient.
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Does it matter how blood pressure is lowered? Of course
it does, but the focus of concern varies according to one’s
perspective. Clinicians worry about pharmacologic
choices. Public health practitioners worry about interven-
tions to change behavior.
Blood pressure is a physical sign that reflects the pres-
sure exerted on the arterial wall, and is determined by the
circulatory volume, the force of cardiac contraction, and
the tonic state of the arterial vessels. Genes and environ-
ment, operating through a variety of neuronal, hormonal,
and cellular mechanisms, together determine the status of
each of these components. The integrated product of
these multiple factors is a blood pressure level that
reflects the sum total of a variety of individual mechanisms.
Moreover, many of these mechanisms are also involved
both in blood pressure control and in the maintenance of
vascular structure and function. Thus, perturbation of
these mechanisms may either elevate blood pressure or
stimulate vascular disease, or both. Presumably, the
strokes and heart attacks that occur with greater fre-
quency in those with elevated blood pressure are most
likely to occur when both blood pressure and vasculotoxic
mechanisms are affected.
From a clinical perspective, the salient point is that the
height of pressure directly relates to cardiovascular disease
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linear relationship between the height of the pressure and
the likelihood of both heart attack and stroke. This has
perhaps best been described through the meta-analysis of
multiple observational studies presented by MacMahon et al
[1]. Most authorities, but not all, now accept the reality that
there is no threshold level by which it is possible to separate
persons with normal from those with abnormal pressures,
but the observed relationship is best understood as reflect-
ing a continuous risk. Nevertheless, on the basis of clinical
trial experience, and by convention, an arbitrary divide has
been applied to invent the condition we term ‘hypertension’.
A growing consensus also supports the view that levels of
blood pressure alone should not determine the need for
therapy. It is but one component of many that defines
absolute risk, which is the appropriate foundation on which
to base therapeutic decisions.
Availability of orally effective antihypertensive agents made
it possible to test, and ultimately confirm the hypothesis
that a reduction in pressure could prevent cardiovascular
events [2]. Early trials, almost always comparing treatment
with diuretics and/or b-blockers with placebo, consistently
showed that the decline in strokes (for a given reduction in
either systolic or diastolic blood pressure, expected by
virtue of the epidemiologic evidence) was actually
achieved. Disappointingly, however, only about half of the
epidemiologically predicted benefit with regard to heart
attack occurred [3].
To my way of thinking, the failure to realize the reduction in
heart attack anticipated by the blood pressure change is
important evidence that the treatment of hypertension is
about more than simply a change in blood pressure. The
fact that, in these trials, the same drugs produced different
results in two blood pressure-related outcomes lends
further weight to the argument that methods of blood
pressure lowering may affect risk.
These clinical trials were not designed to explain these dif-
ferences, nor can they. Perhaps there are adverse conse-
quences of pharmacologic agents that are unrelated to their
blood pressure-lowering effect, which may be observed
and/or unrecognized. Virtually all drugs have actions beyond
those for which they are designed. Diuretics, for example,
have an impact on electrolyte balance, lipid and uric acid
metabolism, and glucose economy, in addition to their
intended hemodynamic effect [4]. The net effect of any par-
ticular class of antihypertensive agents may be the sum of
the benefit produced by a lower blood pressure and the
harmful consequences of its metabolic disturbances.
There is, however, another possibility. Antihypertensive
agents alter blood pressure through different mechanisms.
For example, diuretics act in part by depleting blood
volume. At the same time, they tend to stimulate the renin–
angiotensin system. There is strong experimental and
epidemiologic evidence that an activated renin–angiotensin
system not only tends to increase blood pressure, but is
also vasculotoxic [5]. This undesired hormonal effect
increases the risk for myocardial infarction. Thus, a diuretic
may simultaneously produce opposing effects. By virtue of
its hypotensive property, a diuretic might prevent heart
attacks. At the same time, by activating the renin–
angiotensin system, there might be an increase in heart
attacks. In this case, there would be a dissociation
between the blood pressure effect and the vascular
effects. The unpredictable net health impact would there-
fore be the sum of these conflicting effects.
These clinical studies are consistent with emerging
understanding of the biology of vascular disease. Diuret-
ics provide but one example of how disparate the actions
of these pharmacologic probes may be. New and antici-
pated classes of antihypertensive agents are now charac-
terized according to their unique and vastly differing
effects on vascular structure and function, as well as
according to their hypotensive potential. It seems almost
inevitable that clinical outcomes will also differ in
response to these agents.
Recognition that equal blood pressure reduction may not
always deliver equal cardioprotection has led to formal
comparisons of individual antihypertensive agents. The
largest of these, the National Heart, Lung, and Blood Insti-
tute-sponsored ALLHAT (Antihypertensive and Lipid-Low-
ering Treatment to Prevent Heart Attack Trial) [6], began
in 1993 and has recruited 42000 persons over 55 years.
That study compares three new antihypertensive drug
classes with traditional chlorothalidone. The outcome of
interest is not blood pressure control, but the effect on
stroke and heart attack. Recently, the doxazosin arm of
that study was prematurely terminated because patients
randomized to receive doxazosin experienced significantly
and substantially more cardiovascular disease events than
did chlorothalidone-treated subjects [7]. This result, unan-
ticipated by many, particularly in view of the apparently
favorable profile of metabolic effects associated with this
a-blocker, confirms that equal blood pressure response
does not ensure equal cardiovascular benefit.
To this important experience can be added the results of
several other recently completed trials. The STOP
(Swedish Trial in Old Patients with Hypertension)-2 study
[8] was a comparison of conventional diuretic-based
therapy with angiotensin-converting enzyme (ACE)
inhibitors and calcium channel blockers (CCBs). Overall,
there were no differences in cardiovascular disease event
rates between the conventional and newer therapies.
However, there were significant differences between
CCBs and ACE inhibitors. The latter produced greater
prevention against total cardiovascular events, and partic-
ularly against congestive heart failure, than did CCBs. Ac
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similar advantage of ACE inhibitors over CCBs has been
demonstrated in the ABCD (Trial of Antihypertensive
Therapy in Diabetic Subjects) trial [9]. Finally, there is the
recently reported HOPE (Heart Outcomes Prevention
Evaluation) trial [10]. In that study, it was found that, in
older persons at high risk for cardiovascular events, the
addition of an ACE inhibitor to suitable conventional
therapy generated substantially greater cardioprotection
than did the comparison placebo treatment. Again, the
increment in protection against cardiovascular events
could not be explained by difference in blood pressure. An
attractive candidate to explain the observed outcome
might be vasculoprotection produced by ACE inhibitor-
induced blockade of the renin–angiotensin system.
Regardless of the explanation, it is clear that ACE inhibi-
tion in HOPE resulted in benefits that were independent of
blood pressure. Together, the results of these studies add
up to overpowering evidence that it does matter which
drugs are used to treat hypertension.
At risk of over-simplification, an analogy can be drawn to
the story of fever. At first, an elevated temperature was
itself a disease. It later became clear that fever occurred in
multiple circumstances, including infection. Ultimately,
advances in microbiology and pharmacology made it pos-
sible to match individual therapies with specific infections.
In short, the physical sign of blood pressure no more
defines a homogeneous subgroup than does a particular
level of temperature. Ultimately, however, it seems reason-
able to expect that biomedical science will someday be
able to identify the biologic heterogeneity that is obscured
behind a blood pressure level. This will ultimately lead to
specific disease-preventing therapies.
There are several practical consequences of the realization
that it matters how pressure is reduced. First of all, it will be
difficult for physicians and patients to adopt any antihyper-
tensive agent simply on the premise that blood pressure
reduction will inevitably translate into cardioprotection.
There will also have to be evidence of cardioprotection.
Second, in clinical trials, it can be expected that active anti-
hypertensive controls will replace placebo control.
Nevertheless, although the realization that it matters how
pressure is reduced is important, it will probably not revolu-
tionize clinical practice. Instead, this awareness is more
likely to signal the beginning of simply another, but more
productive chapter in story of blood pressure management.
Superiority of one pharmacologic approach over another in
an aggregate study tells us the average affect. However,
patients are a heterogeneous group of nonaverage individ-
uals. Within this group, not only will individuals differ, but
so too will the causes of their cardiovascular events. That is
why there can be no single universal translation of clinical
trial results. In fact, the physician’s task will remain very
much the same. Therapeutic decisions will still be based
on a wise application of an amalgam of knowledge gained
from physiology and vascular biology, experimentation, and
clinical trial results. Ultimately, ability to both phenotype
and genotype, coupled with a growing armamentarium of
functionally distinct drugs, will make the match of treatment
to patient both more precise, and more effective.
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